Latest Biochip Stories
If you suffer from sepsis, you used to have to wait as much as 48 hours for laboratory findings.
DALLAS, November 12, 2010 /PRNewswire/ -- The 'Top 10 drug discovery technologies (http://www.marketsandmarkets.com/Market-Reports/drug-discovery-41.html) - strategic analysis and global forecasts (2010 to 2015)' analyzes the top 10 drug discovery technologies with respect to market drivers, opportunities and trends in the diverse geographical regions including North America, Europe, Asia and rest of the world. Browse market data tables and in-depth TOC on Top 10 drug discovery...
Circulating tumor cells (CTCs) may be a promising alternative, noninvasive source of tumor materials for biomarker assessment.
SUNNYVALE, Calif., Sept.
BILBAO, Spain, September 27, 2010 /PRNewswire-FirstCall/ -- - LPLchip(R) Rapidly and Precisely Detects Mutations Causing LPL Deficiency, a Cause of Acute Pancreatitis - LPLchip(R) Identifies Patients who Could Benefit From Gene Therapy, Such as AMT's Glybera(R), Currently Under Review for EU Approval Progenika Biopharma S.A., a pioneer in the field of personalized medicine, announced today that it has obtained the CE Mark allowing the sale in Europe of its LPLchip(R), the first...
PARIS, September 13, 2010 /PRNewswire/ -- Biosystems International (BSI), a biotechnology company specializing in the discovery of novel monoclonal antibody based diagnostics, announces its merger with the company MicroBioChips (MBC) by contribution of assets. Advantages of the merger Following a successful partnership to develop monoclonal antibody microarrays, in which BSI provided the antibodies and MBC produced and commercialized the microarrays, the two companies have decided...
DNA microarrays are one of the most powerful tools in molecular biology today.
BARCELONA, June 24 /PRNewswire/ -- Spanish biotechnology company Progenika Biopharma, specializing in the development of personal medicine technology, has granted Grifols exclusive world-wide distribution rights for its BLOODCHIPÂ® molecular biology products.
HEIDELBERG, Germany and LEXINGTON, Mass., June 23 /PRNewswire/ -- febit today announced a restructuring as a consequence of its strategic focus on blood-based microRNA biomarker discovery, febit's major business development in 2009/2010, and on partnerships and intellectual property (IP) commercialization.
ALBUQUERQUE, N.M., April 6 /PRNewswire/ -- Life BioScience, Inc.
- A poem in which the author retracts something said in an earlier poem.